# N4 Pharma plc Nuvec Oral Delivery Update

- Link: https://www.directorstalkinterviews.com/n4-pharma-plc-nuvec-oral-delivery-update/4121136342
- Published: 2023-12-18T07:25:52+00:00
- Author: Emily Johnson

**N4 Pharma Plc** (LON: N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided a positive
update on its ongoing oral delivery research work.

The Company through its research program with the University of Queensland is evaluating
the potential of Nuvec® to act as an oral delivery system for oligonucleotides including
DNA and RNA.

Experiments have now confirmed, _in vivo_, the successful oral administration of
Nuvec® loaded with a DNA plasmid for ovalbumin. The Nuvec® was administered by enteric
coated capsule and the contents, having been released in the intestinal lumen, were
taken up by intestinal cells, with successful transfection and release of the newly
synthesized ovalbumin.

Specifically, the first experiment was a repeat of a study conducted earlier this
year whereby an enterically coated capsule containing Nuvec® loaded with a DNA plasmid
for ovalbumin was administered and protein expression was observed after 3 days.
In this recent experiment, an additional second capsule was administered on day 
3 which resulted in a much higher peak level of expression on days 4-7.

**Nigel Theobald, Chief Executive Officer of N4 Pharma plc, commented:**

_“__This continued success shows that Nuvec® has the potential to be successfully
used as an oral delivery system with many potential applications such as a vaccine,
a product for Irritable Bowel Disease or to treat colonic cancer among many possible
examples. Given the complexities involved in oral delivery this early success with
Nuvec® represents a potentially massive opportunity and point of difference for 
Nuvec® and its use as delivery system to target multiple diseases._

_“With this new data we are in the process of scoping out the next phase of work
to accumulate sufficient data to enable us to focus on a specific oral application
and further news on this will be announced in the new year and we expect to make
advancing Nuvec’s® use as an oral delivery technology a key priority for 2024. In
the meantime, the University of Queensland will continue its work exploring the 
use of Nuvec® as an oral delivery system for vaccines as part of our Australian 
Research Council funded grant with them_.”

Share on: